UKCPO Statement on the UK & Northern Ireland Mounjaro Price Increase

The United Kingdom Coalition for People Living with Obesity (UKCPO) is deeply concerned about the recent announcement that the private price of Eli Lilly’s injectable treatment for type 2 diabetes and weight management will rise by up to 170% in the UK and Northern Ireland from 1 September 2025, following a decision by the manufacturer to “align with EU pricing.”

This sudden and dramatic increase risks putting a proven and effective treatment for obesity and diabetes out of reach for many people who rely on it as part of their ongoing care.

Trusted partners of UKCPO have shared details of this development — you can read more from Ted Kyle’s ConscienHealth coverage here and watch Dr Michael Crotty’s announcement on Facebook.

Impact on People Living with Obesity

For those already prescribed this treatment privately, the sharp increase may cause immediate disruption to treatment plans. Access to effective care is essential for managing obesity, and price rises of this scale can create significant barriers — both financial and emotional.

We strongly recommend contacting your healthcare provider or prescriber as soon as possible for guidance. They can help you explore options such as:

• Adjusting your dosage
• Switching to another medication
• Developing an alternative treatment plan

It’s important to note that this change appears to have not been communicated to healthcare professionals in advance. Your GP or pharmacist is not at fault — many will be learning about this development at the same time as you.

UKCPO’s Position

Obesity is a chronic, relapsing disease requiring long-term, sustainable treatment. Access to effective medication should be based on clinical need — not dictated solely by market forces. Sudden and extreme price changes risk worsening health inequalities and undermining patient care.

UKCPO Executive Director, Ken Clare, said:

“We have had many enquiries from members who are extremely anxious about how they can afford to continue their treatment. People are worried they may have to seek cheaper, less reliable sources, with all the risks that could entail. An increase of up to 170% will put treatment beyond reach for many.”

We encourage everyone living with obesity to rely on trusted, evidence-based sources for updates. UKCPO will keep our website and social media channels updated with the latest verified information.